ICAM1 and pouchitis: Furthermore, alicaforsen, a synthetic antisense oligonucleotide against the adhesion molecule ICAM-1, proved to be effective in patients with UC in phase 2 trials and especially in patients with UC-related pouchitis in phase 3 trials [153,154,155,156,157,158,159,160], whereas in patients with CD, alicaforsen did not significantly improve the clinical outcome [161,162,163,164,165].